Network autumn 2017: Chief Executive's comment
As the UK forges a new relationship with the EU it is vital that negotiations deliver the best possible outcome both for research and for patients in the UK and across the EU.
At the MRC we have long championed the importance of international collaboration for advancing medical research; from research in our units, centres and institutes and partnerships with other funders, to representing the UK on the governing bodies of many international biomedical research organisations, we have supported international health research collaboration for over 80 years.
A recent report, co-funded by eight leading UK medical research funders and charities, highlighted the value of this international collaboration for medical progress (read more on page 4). Any limitations on this ability of researchers and institutions to work together could reduce the impact of science both in the UK and the EU.
The UK makes a significant contribution to the success of medical research across the EU and we are proud to play a leading role. I am particularly keen to do all I can to support the report’s conclusion that international collaboration in medical research must continue after Brexit, a point I will make at every opportunity.
We must do everything in our power to ensure that researchers can continue to work productively through international collaboration.
Sir John Savill
MRC Chief Executive